-, BAY 1841788, Placebo of BAY 1841788 clinical trials

(21140 ARANOTE) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).

This study looks at a new drug, darolutamide, for men with prostate cancer that has spread and still responds to hormone therapy. It compares darolutamide plus standard hormone therapy to a dummy pill plus standard hormone therapy, to see if darolutamide helps patients live longer without their cancer getting worse.